Juvenile Macular Degeneration (Stargardt Disease) – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Juvenile Macular Degeneration (Stargardt Disease) – Pipeline Review, H1 2020’, provides an overview of the Juvenile Macular Degeneration (Stargardt Disease) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Juvenile Macular Degeneration (Stargardt Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Juvenile Macular Degeneration (Stargardt Disease) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Juvenile Macular Degeneration (Stargardt Disease)

– The report reviews pipeline therapeutics for Juvenile Macular Degeneration (Stargardt Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Juvenile Macular Degeneration (Stargardt Disease) therapeutics and enlists all their major and minor projects

– The report assesses Juvenile Macular Degeneration (Stargardt Disease) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Juvenile Macular Degeneration (Stargardt Disease)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Juvenile Macular Degeneration (Stargardt Disease)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Juvenile Macular Degeneration (Stargardt Disease) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Acucela Inc

Alkeus Pharmaceuticals Inc

Alpine Biotherapeutics Corp

Applied Genetic Technologies Corp

Astellas Pharma Inc

Beam Therapeutics Inc

Biogen Inc

Biophytis SA

Cardax Inc

Copernicus Therapeutics Inc

Generation Bio Corp

Grupo Ferrer Internacional SA

Ichor Therapeutics Inc

IVERIC bio Inc

Katairo GmbH

Lin Bioscience Inc

Mediphage Bioceuticals Inc

ProQR Therapeutics NV

Sanofi

Spark Therapeutics Inc

Stargazer Pharmaceuticals Inc

Vision Medicines Inc

Wave Life Sciences Ltd

Table of Contents

Table of Contents

Introduction

Severe Acute Respiratory Syndrome (SARS) - Overview

Severe Acute Respiratory Syndrome (SARS) - Therapeutics Development

Severe Acute Respiratory Syndrome (SARS) - Therapeutics Assessment

Severe Acute Respiratory Syndrome (SARS) - Companies Involved in Therapeutics Development

Severe Acute Respiratory Syndrome (SARS) - Drug Profiles

Severe Acute Respiratory Syndrome (SARS) - Dormant Projects

Severe Acute Respiratory Syndrome (SARS) - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Juvenile Macular Degeneration (Stargardt Disease), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by Acucela Inc, H1 2020

Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by Alkeus Pharmaceuticals Inc, H1 2020

Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by Alpine Biotherapeutics Corp, H1 2020

Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by Applied Genetic Technologies Corp, H1 2020

Juvenile Macular Degeneration (Stargardt Disease) – Pipeline by Astellas Pharma Inc, H1 2020

Juvenile Macular Degeneration (Stargardt Disease) – Dormant Projects, H1 2020

List of Figures

List of Figures

Number of Products under Development for Juvenile Macular Degeneration (Stargardt Disease), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Targets, H1 2020

Number of Products by Stage and Targets, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports